Nanoscope Therapeutics Selects InspiroGene by McKesson to Support Commercial Launch of Novel Retinal Therapy

Nanoscope Therapeutics announced that it has selected InspiroGene by McKesson to provide specialty pharmacy, distribution, and patient support services for its anticipated retinal therapy launch in the United States. The collaboration is intended to strengthen commercialization readiness and streamline supply chain operations as Nanoscope prepares for the potential launch of what it describes as the first optogenetic gene therapy for the U.S. market. The agreement supports Nanoscope’s broader strategy to bring its vision-restoring therapies to patients with retinal degenerative diseases through an integrated distribution and patient access platform.

Learn More